Stoke Therapeutics 配当と自社株買い

配当金基準チェック /06

Stoke Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-9.9%

バイバック利回り

総株主利回り	-9.9%
将来の配当利回り	n/a
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

分析記事 • May 11

Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results

As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...

新しいナラティブ • May 11

Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects

Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • May 01

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Summary I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen. STOK's $390.9M cash position, Biogen partnership, and low burn rate provide runway into mid-2028, mitigating near-term financing risk. Read the full article on Seeking Alpha

分析記事 • Jan 12

Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts

The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...

分析記事 • Dec 05

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry

Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...

分析記事 • Oct 09

Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...

分析記事 • Aug 25

Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...

分析記事 • Aug 15

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate

NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...

分析記事 • May 20

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...

分析記事 • Apr 16

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be

Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...

分析記事 • Apr 05

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...

分析記事 • Feb 26

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Feb 16

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking Alpha

分析記事 • Nov 08

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...

分析記事 • Nov 06

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...

Seeking Alpha • Sep 07

決済の安定と成長

配当データの取得

安定した配当: STOKの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: STOKの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Stoke Therapeutics 配当利回り対市場

STOK 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (STOK)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.2%
業界平均 (Biotechs)	2.4%
アナリスト予想 (STOK) (最長3年)	n/a

注目すべき配当: STOKは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: STOKは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: STOKの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: STOKが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/24 04:01
終値	2026/05/22 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Stoke Therapeutics, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。21

アナリスト	機関
Gregory Harrison	BofA Global Research
Thomas Shrader	BTIG
Michelle Gilson	Canaccord Genuity

Stoke Therapeutics 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects

Stoke Therapeutics Faces Net Loss and Delayed Zorevunersen Data as Insider Selling Draws Attention

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2026

Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026

Chief Medical Officer recently sold US$413k worth of stock

Price target increased by 8.2% to US$45.10

Full year 2025 earnings: EPS and revenues miss analyst expectations

Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome

Consensus EPS estimates increase by 79%

Stoke Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of STK-002

Price target increased by 13% to US$41.89

Price target increased by 8.2% to US$39.63

Investor sentiment deteriorates as stock falls 16%

Price target increased by 8.4% to US$37.13

Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts

Stoke Therapeutics, Inc. Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Consensus EPS estimates increase by 10%

Price target increased by 13% to US$36.63

Price target increased by 8.3% to US$34.25

Advisor & Director exercised options and sold US$467k worth of stock

Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry

Investor sentiment improves as stock rises 15%

Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome

Price target increased by 9.4% to US$30.89

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 21%

Stoke Therapeutics, Inc. Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

New minor risk - Share price stability

Price target increased by 11% to US$27.00

Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%

Price target increased by 10% to US$25.56

Investor sentiment improves as stock rises 16%

Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer

Advisor & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 22%

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Advisor & Director notifies of intention to sell stock

Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Advisor & Director recently sold US$221k worth of stock

Investor sentiment improves as stock rises 37%

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate

Now 23% overvalued after recent price rise

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

Consensus EPS estimates increase by 14%

Investor sentiment improves as stock rises 15%

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 19%

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2025

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be

Consensus revenue estimates decrease by 11%

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 70%

Advisor & Director recently sold US$164k worth of stock

Stoke Therapeutics, Inc. Announces CEO Changes, Effective March 19, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Stoke Therapeutics, Inc. Appoints Arthur Tzianabos as Interim Executive Chairman

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Price target increased by 7.8% to US$24.25

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

New minor risk - Share price stability

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate A Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Chief Medical Officer recently sold US$178k worth of stock

Stoke Therapeutics, Inc. Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Chief Medical Officer exercised options and sold US$115k worth of stock

Stoke Therapeutics, Inc. Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

配当金基準チェック /06